Class III antiarrhythmics: Potassium channel blockers

27,523views

00:00 / 00:00

Videos

Notes

Class III antiarrhythmics: Potassium channel blockers

Cardiovascular system

Antihypertensives

ACE inhibitors, ARBs and direct renin inhibitors

Thiazide and thiazide-like diuretics

Calcium channel blockers

Adrenergic antagonists: Beta blockers

Antianginals

cGMP mediated smooth muscle vasodilators

Calcium channel blockers

Adrenergic antagonists: Beta blockers

Antiarrhythmics

Class I antiarrhythmics: Sodium channel blockers

Class II antiarrhythmics: Beta blockers

Class III antiarrhythmics: Potassium channel blockers

Class IV antiarrhythmics: Calcium channel blockers and others

Lipid-lowering medications

Lipid-lowering medications: Statins

Lipid-lowering medications: Fibrates

Miscellaneous lipid-lowering medications

Positive inotropic medications

Positive inotropic medications

Assessments

Class III antiarrhythmics: Potassium channel blockers

Flashcards

0 / 27 complete

Flashcards

Class III antiarrhythmics: Potassium channel blockers

of complete

External References

First Aid

2022

2021

2020

2019

2018

2017

2016

Amiodarone p. 329

hypothyroidism p. 250

hypothyroidism with p. 347

photosensitivity p. 251

pulmonary fibrosis p. 252

restrictive lung disease p. 700

Bradycardia

amiodarone and p. 329

Haptens

amiodarone as p. 329

Heart failure p. 318

amiodarone p. 329

Hepatotoxicity

amiodarone p. 329

Hyperthyroidism p. 346, 348, 671

amiodarone and p. 329

Hypothyroidism p. 346, 347

amiodarone and p. 329

Pulmonary fibrosis

amiodarone and p. 329

Transcript

Content Reviewers

Elizabeth Nixon-Shapiro, MSMI, CMI

Marisa Pedron

Contributors

Filip Vasiljević, MD

Evan Debevec-McKenney

Ursula Florjanczyk, MScBMC

Antiarrhythmic medications help control arrhythmias, or abnormal heart beats.

There are five main groups of antiarrhythmic medications: class I, also known as sodium-channel blockers; class II, also called beta-blockers; class III, also known as potassium-channel blockers; class IV, also called calcium-channel blockers; and miscellaneous antiarrhythmics, or unclassified antiarrhythmics. Now, we’ll focus on class III antiarrhythmic medications.

Normally, an electrical signal starts at the sinoatrial or SA node in the right atrium, then propagates out through both atria, making them contract.

The signal gets delayed a bit as it goes through the atrioventricular or AV node, then goes through the Bundle of His to the Purkinje fibers of both ventricles, making them contract as well.

When the signal doesn’t follow this pathway, we get abnormal heartbeats called an arrhythmia, and there are two main causes - abnormal automaticity and abnormal reentry.

Abnormal automaticity is when an area of the heart, say, a part of the ventricle, begins to fire off action potentials at a rate that’s even faster than the SA node.

As a result, this area of the heart essentially flips roles with the SA node, firing so fast that the pacemaker cells in the SA node don’t get a chance to fire. At that point, the heartbeat is being driven by the ventricles.

Alternatively, there can be an abnormal reentry which often results from scar tissue in a ventricle after a heart attack.

Scar tissue doesn’t conduct electricity, so the signal just goes around and around the scar, and each cycle can cause the ventricles to contract.

Alternatively, there might be an accessory, or extra pathway between the atria and the ventricles, like the bundle of Kent in Wolff-Parkinson-White syndrome.

Here, the signal might move back up the accessory pathway, since oftentimes it’s bidirectional, meaning the signal can go from atrium to ventricle as well as from ventricle to atrium.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Therapeutic drug monitoring: antiarrhythmic drugs" British Journal of Clinical Pharmacology (1998)
  4. "Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study" BioMedical Engineering OnLine (2017)
  5. "Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy" Vascular Health and Risk Management (2010)
  6. "Dronedarone for the treatment of atrial fibrillation and atrial flutter" Health Technology Assessment (2010)
  7. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
Elsevier

Copyright © 2023 Elsevier, except certain content provided by third parties

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX